Proactiveinvestors recommends
Stocktube video
16/04/2013

Fusion IP should see 'quite a significant' rise in spin-outs

View full size
Additional Information
Market: AIM
Sector: Technology Hardware & Equipment
EPIC: FIP
Latest Price: 58.50p  (2.63% Ascending)
52-week High: 81.00p
52-week Low: 40.50p
Market Cap: 64.02M
1 year chart More charts
digital-look imported chart image
Deal FIP Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
digital-look imported chart image
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Fusion IP
www.fusionip.co.uk
Deal Fusion IP Tax Free* Losses can exceed
your initial deposit *subject to change and depends on individual circumstances.

Fusion IP owns the rights to 100% of university-owned research generated at two of the UK's leading universities – The University of Sheffield and Cardiff University. These exclusive partnerships enable us to develop some of the world's most advanced and exciting science, in fields as varied as clean energy, electronics, engineering...

Read more
Full Fusion IP profile here
Pdf

UPDATE - Fusion IP company raises £1 million to fast track US sales

August 01 2012, 1:38pm ScanTrainer is a virtual ‘real feel’ ultrasound simulator that imitates a real ultrasound scanning experience without the need for a real machine or a patient.

---adds broker comments and share price---

Fusion IP (LON:FIP) has invested a further £300,000 into portfolio company MedaPhor as part of a £1 million funding to accelerate US sales and develop its ultrasound training simulator.

Medical training specialist MedaPhor, in which Fusion has a 35 per cent interest, raised £1.06 million in an equity funding round to help speed up US sales and the development of its baby scanning simulator ScanTrainer.

The Cardiff-based company’s product is a virtual ‘real feel’ ultrasound simulator that imitates a real ultrasound scanning experience without the need for a real machine or a patient.

“MedaPhor has made excellent progress over the last two years and we are delighted to continue to support the company, as it expands its sales into the US,” said Fusion’s chief executive David Baynes.

“The company has sold 70 per cent more in the first 6 months of 2012 than it did in the whole of 2011 and we look forward to watching the company continue to grow as it develops its US sales force and launches its new abdominal scanning system in 2013.”

Along with converting existing loan notes of £150,000, Fusion invested £300,000 of new money in the round, taking its undiluted shareholding to 39 per cent.

The rest of the money was put up by Finance Wales, which brought its total investment to over £700,000 by matching Fusion’s investment, while fellow portfolio firm IP Group (LON:IPO) invested £450,000 in the round.

ScanTrainer has been selling in the UK and MedaPhor recently made its first US, European and Australian sales.

Seymour Pierce called MedaPhor “an exciting business and opportunity within the Fusion IP stable”.

The broker reiterated its ‘buy’ rating on Fusion and target price of 80 pence, which suggests considerable upside to the current market price of 47.6 pence, up 3.5 per cent today.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.